16264 Federal Register / Vol. 77, No. 54 / Tuesday, March 20, 2012 / Notices 

factors in 21 U.S.C. 823(a), and 

determined that the registration of 

Johnson Matthey Inc. to manufacture 

the listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Johnson Matthey Inc. to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: March 8, 2012. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2012–6720 Filed 3–19–12; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances, Notice of Registration; 

Johnson Matthey Pharmaceutical 

Materials Inc. 

By Notice dated November 18, 2011, 

and published in the Federal Register 

on November 28, 2011, 76 FR 72974, 

Johnson Matthey Pharmaceutical 

Materials Inc., Pharmaceutical Service, 

25 Patton Road, Devens, Massachusetts 

01434, made application by renewal to 

the Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the following basic 

classes of controlled substances: 

Drug Schedule 

Amphetamine (1100) .................... II 

Methylphenidate (1724) ................ II 

Nabilone (7379) ............................ II 

Hydrocodone (9193) ..................... II 

Alfentanil (9737) ........................... II 

Remifentanil (9739) ...................... II 

Sufentanil (9740) .......................... II 

The company plans to utilize this 

facility to manufacture small quantities 

of the listed controlled substances in 

bulk and to conduct analytical testing in 

support of the company’s primary 

manufacturing facility in West Deptford, 

New Jersey. The controlled substances 

manufactured in bulk at this facility will 

be distributed to the company’s 

customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a), and 

determined that the registration of 

Johnson Matthey Pharmaceutical 

Materials Inc. to manufacture the listed 

basic classes of controlled substances is 

consistent with the public interest at 

this time. DEA has investigated Johnson 

Matthey Pharmaceutical Materials Inc. 

to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: March 8, 2012. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2012–6703 Filed 3–19–12; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances, Notice of Registration; 

Noramco Inc. (GA) 

By Notice dated November 21, 2011, 

and published in the Federal Register 

on November 29, 2011, 76 FR 73679, 

Noramco Inc., 1440 Olympic Drive, 

Athens, Georgia 30601, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the following basic classes of controlled 

substances: 

Drug Schedule 

Codeine-N-oxide (9053) ............... I 

Dihydromorphine (9145) ............... I 

Morphine-N-oxide (9307) ............. I 

Amphetamine (1100) .................... II 

Methylphenidate (1724) ................ II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Hydrocodone (9193) ..................... II 

Morphine (9300) ........................... II 

Oripavine (9330) ........................... II 

Thebaine (9333) ........................... II 

Oxymorphone (9652) ................... II 

Noroxymorphone (9668) .............. II 

Drug Schedule 

Alfentanil (9737) ........................... II 

Sufentanil (9740) .......................... II 

Carfentanil (9743) ......................... II 

Tapentadol (9780) ........................ II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Noramco Inc., to manufacture the listed 

basic classes of controlled substances is 

consistent with the public interest at 

this time. DEA has investigated 

Noramco Inc., to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: March 8, 2012. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2012–6698 Filed 3–19–12; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances, Notice of Registration; 

Halo Pharmaceutical Inc. 

By Notice dated December 2, 2011, 

and published in the Federal Register 

on December 14, 2011, 76 FR 77850, 

Halo Pharmaceutical Inc., 30 North 

Jefferson Road, Whippany, New Jersey 

07981, made application by renewal to 

the Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the following basic 

classes of controlled substances: 

Drug Schedule 

Dihydromorphine (9145) ............... I 

Hydromorphone (9150) ................ II 

Dihydromorphine is an intermediate 

in the manufacture of Hydromorphone 

and is not for commercial distribution. 


srobinson on DSK4SPTVN1PROD with NOTICES
Federal Register / Vol. 77, No. 54 / Tuesday, March 20, 2012 / Notices 16265 

The company plans to manufacture 

Hydromorphone HCL for sale to other 

manufacturers and for the manufacture 

of other controlled substance dosage 

units for distribution to its customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of Halo 

Pharmaceutical Inc. to manufacture the 

listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Halo Pharmaceutical Inc. to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: March 8, 2012. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2012–6696 Filed 3–19–12; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF LABOR 

Office of the Secretary 

Agency Information Collection 

Activities; Submission for OMB 

Review; Comment Request; PermitRequired Confined Spaces Standard 

ACTION: Notice. 

SUMMARY: The Department of Labor 

(DOL) is submitting the Occupational 

Safety and Health Administration 

(OSHA) sponsored information 

collection request (ICR) titled, ‘‘PermitRequired Confined Spaces Standard,’’ to 

the Office of Management and Budget 

(OMB) for review and approval for 

continued use in accordance with the 

Paperwork Reduction Act (PRA) of 1995 

(44 U.S.C. 3501 et seq.). 

DATES: Submit comments on or before 

April 19, 2012. 

ADDRESSES: A copy of this ICR with 

applicable supporting documentation; 

including a description of the likely 

respondents, proposed frequency of 

response, and estimated total burden 

may be obtained from the RegInfo.gov 

Web site, http://www.reginfo.gov/ 

public/do/PRAMain, on the day 

following publication of this notice or 

by contacting Michel Smyth by 

telephone at 202–693–4129 (this is not 

a toll-free number) or sending an email 

to DOL_PRA_PUBLIC@dol.gov. 

Submit comments about this request 

to the Office of Information and 

Regulatory Affairs, Attn: OMB Desk 

Officer for the DOL–OSHA, Office of 

Management and Budget, Room 10235, 

Washington, DC 20503, Telephone: 

202–395–6929/Fax: 202–395–6881 

(these are not toll-free numbers), email: 

OIRA_submission@omb.eop.gov. 

FOR FURTHER INFORMATION CONTACT: 

Michel Smyth by telephone at 202–693– 

4129 (this is not a toll-free number) or 

by email at DOL_PRA_PUBLIC@dol.gov. 

SUPPLEMENTARY INFORMATION: Under the 

authority granted by the Occupational 

Safety and Health Act, 29 U.S.C. 651 et 

seq., the OSHA published at 29 CFR 

1910.146 a safety standard for general 

industry regulating permit-required 

confined spaces, including requirements 

for developing and maintaining 

inspection records used by employers 

and employees whenever entry is made 

into permit-required confined spaces. 

This information collection is subject to 

the PRA. 

A Federal agency generally cannot 

conduct or sponsor a collection of 

information, and the public is generally 

not required to respond to an 

information collection, unless it is 

approved by the OMB under the PRA 

and displays a currently valid OMB 

Control Number. In addition, 

notwithstanding any other provisions of 

law, no person shall generally be subject 

to penalty for failing to comply with a 

collection of information if the 

collection of information does not 

display a valid OMB Control Number. 

See 5 CFR 1320.5(a) and 1320.6. The 

DOL obtains OMB approval for this 

information collection under OMB 

Control Number 1218–0203. The current 

OMB approval is scheduled to expire on 

March 31, 2012; however, it should be 

noted that existing information 

collection requirements submitted to the 

OMB receive a month-to-month 

extension while they undergo review. 

For additional information, see the 

related notice published in the Federal 

Register on December 14, 2011 (76 FR 

77850). 

Interested parties are encouraged to 

send comments to the OMB, Office of 

Information and Regulatory Affairs at 

the address shown in the ADDRESSES

section within 30 days of publication of 

this notice in the Federal Register. In 

order to help ensure appropriate 

consideration, comments should 

reference OMB Control Number 1218– 

0203. The OMB is particularly 

interested in comments that: 

• Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

• Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

• Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

• Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses. 

Agency: DOL–OSHA. 

Title of Collection: Permit-Required 

Confined Spaces Standard. 

OMB Control Number: 1218–0203. 

Affected Public: Private sector— 

Businesses or Other For-Profits. 

Total Estimated Number of 

Respondents: 209,045. 

Total Estimated Number of 

Responses: 8,644,934. 

Total Estimated Annual Burden 

Hours: 1,433,443. 

Total Estimated Annual Other Costs 

Burden: $0. 

Dated: March 14, 2012. 

Michel Smyth, 

Departmental Clearance Officer. 

[FR Doc. 2012–6678 Filed 3–19–12; 8:45 am] 

BILLING CODE 4510–26–P 

DEPARTMENT OF LABOR 

Office of the Secretary 

Agency Information Collection 

Activities; Submission for OMB 

Review; Comment Request; Job 

Openings and Labor Turnover Survey 

ACTION: Notice. 

SUMMARY: The Department of Labor 

(DOL) is submitting the Bureau of Labor 

Statistics (BLS) sponsored information 

collection request (ICR) revision titled, 

‘‘Job Openings and Labor Turnover 

Survey,’’ (JOLTS) to the Office of 

Management and Budget (OMB) for 

review and approval for use in 

accordance with the Paperwork 

Reduction Act (PRA) of 1995 (44 U.S.C. 

3501 et seq.). 


srobinson on DSK4SPTVN1PROD with NOTICES